UNSPSC 51172103: Pitofenone or pitofenone hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C22H25NO4 and C22H25NO4.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers M09N8K7YJY and HE1ZA4ZBEX. European Medicines Agency schedules Pitofenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB09946MIG and SUB03880MIG. The term PITOFENONE is an International Non-Proprietary Name or INN. PITOFENONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51172103 Pitofenone or pitofenone hydrochloride is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local procurement activity shows little direct relevance to this narrow chemical specification. The three most recent opportunities posted under or adjacent to this code span offender drug testing services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical supply agreements — none of which explicitly solicit pitofenone or pitofenone hydrochloride as a line item. The mismatch between the code's name and the scope of actual procurements suggests either miscoding by the issuing jurisdictions or a gap between the taxonomy and how state and local governments tag pharmaceutical-related services and supplies in practice.

Issuing bodies include Collin County Community Supervision and Corrections Department (Texas), the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple states including Oregon. Recent activity concentrates in Texas and Minnesota. The most concrete solicitation is Collin County's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 over two years; the county seeks lab-certified vendors to conduct approximately 25,031 annual tests using immunoassay screening with LC/MS/MS or GC/MS confirmation, with optional oral fluid and hair testing. The Texas HHS Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for self-insured health plans, without formal award values or timelines at that exploratory stage. MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, sought manufacturers supplying products through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and contract effective July 1, 2026. These opportunities do not appear to target pitofenone specifically; a vendor evaluating pursuit under this code should verify whether state and local buyers are actually requesting this ingredient or whether the code assignment reflects procurement-system data-quality issues rather than genuine demand.